Short bowel syndrome

Displaying 5 studies

  • Comparison of Different Oral Rehydration Solutions Rochester, MN

    Compliance is the biggest challenge in patients with Short Bowel Syndrome (SBS) on Home Parenteral Nutrition. These patients need to hydrate themselves to meet the excess fluid loss due to their anatomy. Oral Rehydration Solution (ORS) is prescribed to all these patients. The investigators believe that taste of the standard ORS is the biggest reason why these patients are not compliant. The new ORS in the market has been prepared with this in mind. The investigators want to study if this new ORS will improve the compliance in this patient cohort.

  • Short Bowel Syndrome and Teduglutide VS Placebo Rochester, MN

    Investigator plans to examine the gastrointestinal (GI) physiologic profile of Teduglutide, a Glucagon-like Peptide 2 Analog as a possible intestinotrophic growth factor capable of inducing small bowel adaptation and regeneration in patients with short bowel syndrome (SBS), with the potential to decrease parenteral nutrition dependence.

  • Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS Rochester, MN; Scottsdale/Phoenix, AZ

    The primary objective of the trial is to evaluate the long-term safety of glepaglutide treatment in patients with short bowel syndrome (SBS). Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.

  • A Study to Evaluate the Effectiveness and Safety of Glepaglutide in the Treatment of Short Bowel Syndrome Scottsdale/Phoenix, AZ; Rochester, MN

    The primary purpose of this trial is to confirm the effectiveness of glepaglutide in reducing parenteral support volume in patients with short bowel syndrome. Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.

  • A Study to Evaluate the Effectiveness and Safety of Apraglutide in Adults with Short Bowel Syndrome and Intestinal Failure Rochester, MN

    The primary purpose of this study is to evaluate the effectiveness of Apraglutide (5 mg subcutaneously (SC), once weekly) in reducing the administered volume per week of PS from baseline, compared with placebo in adults with Short Bowel Syndrome and Intestinal Failure.

    Short bowel syndrome is a malabsorptive condition characterized by extreme reduction in functional small intestinal length most commonly as a result of surgical resection due to mesenteric ischemia or Inflammatory Bowel Disease (IBD) although other etiologies are also present. 

.

Mayo Clinic Footer